Vladimir Coric
Chief Executive Officer chez BIOHAVEN LTD.
Fortune : 172 M $ au 31/03/2024
Profil
Le Dr Vlad Coric, MD, est directeur général et directeur de Biohaven Pharmaceutical Holding Co. Ltd. et professeur clinicien associé à la Yale School of Medicine. Il est membre du conseil d'administration de Biohaven Pharmaceutical Holding Co. Ltd, Our Lady of Mercy Academy, Pyramid Biosciences, Inc. et Vita Therapeutics, Inc. Le Dr Coric était auparavant employé comme directeur de groupe pour la recherche clinique mondiale chez Bristol Myers Squibb Co. et comme président de la Connecticut Psychiatric Society. Il a obtenu son doctorat à la Wake Forest School of Medicine.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
BIOHAVEN LTD.
3,85% | 22/04/2024 | 3 146 085 ( 3,85% ) | 172 M $ | 31/03/2024 |
08/03/2024 | 5 784 ( 0,01% ) | 28 457 $ | 31/03/2024 |
Postes actifs de Vladimir Coric
Sociétés | Poste | Début |
---|---|---|
BIOHAVEN LTD. | Chief Executive Officer | 02/05/2022 |
REVANCE THERAPEUTICS, INC. | Director/Board Member | 01/03/2023 |
Yale School of Medicine | Corporate Officer/Principal | 01/07/2001 |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Director/Board Member | - |
Our Lady of Mercy Academy | Director/Board Member | - |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Director/Board Member | - |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Chief Executive Officer | - |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Director/Board Member | - |
Anciens postes connus de Vladimir Coric
Sociétés | Poste | Fin |
---|---|---|
BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. | Chief Executive Officer | 03/10/2022 |
░░░░ ░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░░░ ░░░░░░ ░░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
░░░░░░░░░░░ ░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░ | - |
Formation de Vladimir Coric
Wake Forest School of Medicine | Doctorate Degree |
University of Connecticut | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
REVANCE THERAPEUTICS, INC. | Health Technology |
BIOHAVEN LTD. | Health Technology |
Entreprise privées | 8 |
---|---|
Biohaven Pharmaceutical Holding Co. Ltd.
Biohaven Pharmaceutical Holding Co. Ltd. Pharmaceuticals: MajorHealth Technology Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT. | Health Technology |
Our Lady of Mercy Academy | |
Connecticut Psychiatric Society | |
Biohaven Pharmaceuticals, Inc.
Biohaven Pharmaceuticals, Inc. Miscellaneous Commercial ServicesCommercial Services Biohaven Pharmaceuticals, Inc. engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company in July 2013 and is headquartered in New Haven, CT. | Commercial Services |
Pyramid Biosciences, Inc.
Pyramid Biosciences, Inc. BiotechnologyHealth Technology Pyramid Biosciences, Inc. operates as a biotechnology company. It develops new therapies focused on the modulation of cell surface. The company was founded by Kollol Pal and Jordan Leef and is headquartered in Waltham, MA. | Health Technology |
Vita Therapeutics, Inc.
Vita Therapeutics, Inc. BiotechnologyHealth Technology Vita Therapeutics, Inc. is a biotechnology company based in Baltimore, MD that develops state-of-the-art cellular therapeutics for the treatment of neuromuscular diseases and cancers. The company uses induced pluripotent stem cell (iPSC) technology to engineer specific cell types designed to replace those that are defective in patients. Vita Therapeutics is progressing its co-leading programs VTA-100 and VTA-300 for the treatment of limb-girdle muscular dystrophy (LGMD) and multiple solid tumors with the goal of filing investigational drug applications with the Food and Drug Administration in 2023. The company is developing these proprietary cellular therapies following a dual development strategy beginning with autologous-derived cells before moving to a universal hypoimmunogenic cell line. Vita Therapeutics was founded in 2019 by Douglas Taylor Falk, M.S. and Peter Andersen, Ph.D. Douglas Taylor Falk has been the CEO since 2019. | Health Technology |
Veradermics, Inc.
Veradermics, Inc. Pharmaceuticals: MajorHealth Technology VeraDermics, Inc. is a clinical-stage biopharmaceutical company that focuses on developing drugs for immunologic and dermatologic diseases. The company is based in San Antonio, TX. The company has a portfolio of five product candidates that target common skin conditions such as warts, hair loss, and eczema. Founded by dermatologists, VeraDermics leverages its clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. | Health Technology |
Social Capital Suvretta Holdings Corp. I
Social Capital Suvretta Holdings Corp. I Financial ConglomeratesFinance Social Capital Suvretta Holdings Corp. I is a blank check company, which engages in effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. It focuses on the search for target business operating in the biotechnology industry and within the neurology subsector. The company was founded by Chamath Palihapitiya and Kishen C. Mehta on February 25, 2021 and is headquartered in Henderson, NV. | Finance |